Bioparticle-based delivery system offers potential as a coronavirus therapy LOS ANGELES–(BUSINESS WIRE)–An emerging company developing biotechnology invented at UCLA is
Mylan is potentially getting access to 14 indications after approval, as first neurotoxin formulation to be developed as a potential biosimilar product to BOTOX.
FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced the U.S. Food and Drug Administration
Longhorn Vaccines & Diagnostics and Cenetron Diagnostics Team up with Coca-Cola Bottlers to Produce COVID-19 Test Kits
BETHESDA, Md. & AUSTIN, Texas–(BUSINESS WIRE)–Longhorn Vaccines & Diagnostics, an innovative molecular tool, assay and vaccine development company focused on
NEW YORK–(BUSINESS WIRE)–Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that members of
CORRECTING and REPLACING Schultze Special Purpose Acquisition Corp. Announces Non-Binding Letter of Intent for a Business Combination with Clever Leaves, a Leading Pharmaceutical-Grade Multi-National Cannabis Operator
-With More than 1.9 Million Square Feet of Greenhouses, Clever Leaves is One of the Largest Cannabis Cultivation and Extraction
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Resolution of middle ear effusion in 56% of OP0201 vs. 38% of placebo patients (p=0.07) Company engages financial advisors to
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
— Important Data on Psychosocial Burden of Peanut Allergy on Children and Caregivers Also to be Presented — BRISBANE, Calif.–(BUSINESS
Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research
Awards program underscores the importance of critical clinical research to deepen understanding of pulmonary disease to help improve patient outcomes
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.